Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Happy New Year, biotech friends! We’re back with news, including Merck’s decision to cut the price of its diabetes drug Januvia by 42% and Neumora’s readout on its experimental depression drug.